Crizotinib in ROS1 and MET Deregulated NSCLC-Letter.
2020
In the METROS trial, Landi and colleagues evaluated the efficacy of crizotinib in advanced non–small cell lung cancer (NSCLC) harboring ROS1 rearrangements or MET dysregulation ([1][1]). A total of 505 patients were screened and 10 patients entered the trial with cancers harboring MET exon 14
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
5
References
2
Citations
NaN
KQI